Marksans Pharma Limited (MARKSANS.BO)
INR 314.2
(-2.1%)
INR 314.2
(-2.1%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.29 Billion INR | -65.52% |
| 2022 | -2.59 Billion INR | -171.36% |
| 2021 | -956.28 Million INR | 45.41% |
| 2020 | -1.75 Billion INR | -175.99% |
| 2019 | -634.7 Million INR | -194.22% |
| 2018 | 673.61 Million INR | -13.91% |
| 2017 | 782.45 Million INR | -7.58% |
| 2016 | 846.6 Million INR | 60.12% |
| 2015 | 528.74 Million INR | 183.59% |
| 2014 | -632.53 Million INR | -180.67% |
| 2013 | 784.07 Million INR | -25.88% |
| 2012 | 1.05 Billion INR | -0.89% |
| 2011 | 1.06 Billion INR | 995.71% |
| 2010 | -119.16 Million INR | -103.07% |
| 2009 | 3.88 Billion INR | 3.83% |
| 2008 | 3.74 Billion INR | 35.44% |
| 2007 | 2.76 Billion INR | 72.65% |
| 2006 | 1.6 Billion INR | 50.61% |
| 2005 | 1.06 Billion INR | 32.74% |
| 2004 | 800.48 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 100.0% |
| 2023 Q1 | 7.15 Billion INR | 375.85% |
| 2023 Q2 | -2.47 Billion INR | -134.56% |
| 2023 FY | -4.29 Billion INR | -65.52% |
| 2023 Q4 | -4.29 Billion INR | -164.97% |
| 2023 Q3 | 6.61 Billion INR | 367.27% |
| 2022 Q4 | -2.59 Billion INR | -177.37% |
| 2022 FY | -2.59 Billion INR | -171.36% |
| 2022 Q2 | -1.44 Billion INR | -141.4% |
| 2022 Q1 | 3.49 Billion INR | 465.69% |
| 2022 Q3 | 3.35 Billion INR | 331.67% |
| 2021 Q4 | -956.28 Million INR | -129.63% |
| 2021 Q2 | -2.82 Billion INR | -232.85% |
| 2021 Q1 | 2.12 Billion INR | 221.19% |
| 2021 FY | -956.28 Million INR | 45.41% |
| 2021 Q3 | 3.22 Billion INR | 214.42% |
| 2020 Q3 | 1.54 Billion INR | 216.53% |
| 2020 Q1 | 937.26 Million INR | 247.67% |
| 2020 Q2 | -1.32 Billion INR | -241.36% |
| 2020 Q4 | -1.75 Billion INR | -213.46% |
| 2020 FY | -1.75 Billion INR | -175.99% |
| 2019 FY | -634.7 Million INR | -194.22% |
| 2019 Q3 | 477.55 Million INR | 81.69% |
| 2019 Q1 | 335.38 Million INR | -50.21% |
| 2019 Q2 | 262.84 Million INR | -21.63% |
| 2019 Q4 | -634.7 Million INR | -232.91% |
| 2018 Q3 | 350.39 Million INR | -30.39% |
| 2018 FY | 673.61 Million INR | -13.91% |
| 2018 Q2 | 503.33 Million INR | 26.06% |
| 2018 Q1 | 399.27 Million INR | -48.97% |
| 2018 Q4 | 673.61 Million INR | 92.25% |
| 2017 Q1 | 251.62 Million INR | -70.28% |
| 2017 FY | 782.45 Million INR | -7.58% |
| 2017 Q4 | 782.45 Million INR | 37.2% |
| 2017 Q3 | 570.29 Million INR | -42.05% |
| 2017 Q2 | 984.07 Million INR | 291.09% |
| 2016 FY | 846.6 Million INR | 60.12% |
| 2016 Q1 | 353.01 Million INR | -33.24% |
| 2016 Q2 | 782.63 Million INR | 121.7% |
| 2016 Q4 | 846.6 Million INR | 354.87% |
| 2016 Q3 | 186.12 Million INR | -76.22% |
| 2015 Q4 | 528.74 Million INR | 22.1% |
| 2015 Q3 | 433.05 Million INR | -34.21% |
| 2015 Q2 | 658.24 Million INR | -64.47% |
| 2015 Q1 | 1.85 Billion INR | 392.89% |
| 2015 FY | 528.74 Million INR | 183.59% |
| 2014 Q1 | 469.47 Million INR | -40.12% |
| 2014 Q4 | -632.53 Million INR | -162.13% |
| 2014 Q3 | 1.01 Billion INR | 69.12% |
| 2014 Q2 | 601.97 Million INR | 28.22% |
| 2014 FY | -632.53 Million INR | -180.67% |
| 2013 Q1 | 158.8 Million INR | -84.99% |
| 2013 Q2 | 1.2 Billion INR | 658.66% |
| 2013 Q3 | 67.74 Million INR | -94.38% |
| 2013 Q4 | 784.07 Million INR | 1057.36% |
| 2013 FY | 784.07 Million INR | -25.88% |
| 2012 FY | 1.05 Billion INR | -0.89% |
| 2012 Q2 | 89.82 Million INR | 0.0% |
| 2012 Q4 | 1.05 Billion INR | 0.0% |
| 2011 FY | 1.06 Billion INR | 995.71% |
| 2010 FY | -119.16 Million INR | -103.07% |
| 2009 FY | 3.88 Billion INR | 3.83% |
| 2008 FY | 3.74 Billion INR | 35.44% |
| 2007 FY | 2.76 Billion INR | 72.65% |
| 2006 FY | 1.6 Billion INR | 50.61% |
| 2005 FY | 1.06 Billion INR | 32.74% |
| 2004 FY | 800.48 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Abbott India Limited | -20.51 Billion INR | 79.061% |
| Cipla Limited | -3.15 Billion INR | -36.112% |
| Gland Pharma Limited | -14.67 Billion INR | 70.727% |
| GlaxoSmithKline Pharmaceuticals Limited | -674.11 Million INR | -537.16% |
| Kopran Limited | 850.3 Million INR | 605.133% |
| NGL Fine-Chem Limited | 307.22 Million INR | 1498.055% |
| Pfizer Limited | -19.52 Billion INR | 77.998% |
| Sanofi India Limited | -3.87 Billion INR | -10.843% |
| SMS Pharmaceuticals Limited | 2.44 Billion INR | 275.622% |